Leticia Aptecar1, Frederic Fiteni2,3, Marta Jarlier4, Stephanie Delaine5, Violaine Guillerme6, William Jacot1,7, Veronique D'Hondt8,9. 1. Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France. 2. Medical Oncology Department, Centre Hospitalier Universitaire de Nimes, Nimes, France. 3. Institut Desbrest d'Epidemiologie et de Sante Publique, University of Montpellier, Montpellier, France. 4. Biometrics Unit, Institut du Cancer de Montpellier, Montpellier, France. 5. Medical Research Unit, Institut du Cancer de Montpellier, Montpellier, France. 6. Centre Hospitalier Bretagne Atlantique, Auray, France. 7. Institut de Recherche en Cancerologie de Montpellier (IRCM), INSERM, University of Montpellier, Montpellier, France. 8. Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France. veronique.dhondt@icm.unicancer.fr. 9. Institut de Recherche en Cancerologie de Montpellier (IRCM), INSERM, University of Montpellier, Montpellier, France. veronique.dhondt@icm.unicancer.fr.
Abstract
PURPOSE: Sexual quality of life (QoL) is affected during and after breast cancer (BC) treatment and is not specifically evaluated with the general health-related quality-of-life questionnaires EORTC QLQ-C30 or QLQ-BR23. A specific questionnaire, the EORTC SHQ-C22, including physical, psychological, and social aspects of sexuality, was recently developed to address this issue in cancer patients. METHODS: A prospective bicentric study was conducted to evaluate the sexual QoL of women with BC during the first year of adjuvant hormonal treatment. RESULTS: A total of 106 women completed the 3 questionnaires at baseline and 92 of them, at 12 months. At baseline, we showed low sexual satisfaction and importance given to sexual activity and a very low communication with healthcare professionals about this issue. Twelve months later, the importance given to sexuality had increased. While the communication with professionals had improved, it remained at a very low level. We were unable to identify specific clinical factors (chemotherapy, menopausal status, type of surgery or radiotherapy) that would negatively affect the global sexual well-being in BC patients. CONCLUSION: The analysis of sexual QoL of BC patients during the first year of hormonal treatment with a recently developed, cancer-dedicated, standardized tool pointed out the need for deeper communication between professionals and patients regarding sexual issues to fill the current gap in care of cancer patients and help patients with adequate intervention and support.
PURPOSE: Sexual quality of life (QoL) is affected during and after breast cancer (BC) treatment and is not specifically evaluated with the general health-related quality-of-life questionnaires EORTC QLQ-C30 or QLQ-BR23. A specific questionnaire, the EORTC SHQ-C22, including physical, psychological, and social aspects of sexuality, was recently developed to address this issue in cancerpatients. METHODS: A prospective bicentric study was conducted to evaluate the sexual QoL of women with BC during the first year of adjuvant hormonal treatment. RESULTS: A total of 106 women completed the 3 questionnaires at baseline and 92 of them, at 12 months. At baseline, we showed low sexual satisfaction and importance given to sexual activity and a very low communication with healthcare professionals about this issue. Twelve months later, the importance given to sexuality had increased. While the communication with professionals had improved, it remained at a very low level. We were unable to identify specific clinical factors (chemotherapy, menopausal status, type of surgery or radiotherapy) that would negatively affect the global sexual well-being in BC patients. CONCLUSION: The analysis of sexual QoL of BC patients during the first year of hormonal treatment with a recently developed, cancer-dedicated, standardized tool pointed out the need for deeper communication between professionals and patients regarding sexual issues to fill the current gap in care of cancerpatients and help patients with adequate intervention and support.
Entities:
Keywords:
Adjuvant hormonal treatment; Breast cancer; EORTC SHQ-C22; Sexual quality of life
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: Karin Ribi; Weixiu Luo; Barbara A Walley; Harold J Burstein; Jacquie Chirgwin; Rafat H Ansari; Muhammed Salim; Andre van der Westhuizen; Ehtesham Abdi; Prudence A Francis; Stephen Chia; Vernon J Harvey; Anita Giobbie-Hurder; Gini F Fleming; Olivia Pagani; Angelo Di Leo; Marco Colleoni; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Meredith M Regan; Jürg Bernhard Journal: Breast Cancer Res Treat Date: 2020-04-09 Impact factor: 4.872
Authors: Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen A Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2018-11-19 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Carolyn D Runowicz; Corinne R Leach; N Lynn Henry; Karen S Henry; Heather T Mackey; Rebecca L Cowens-Alvarado; Rachel S Cannady; Mandi L Pratt-Chapman; Stephen B Edge; Linda A Jacobs; Arti Hurria; Lawrence B Marks; Samuel J LaMonte; Ellen Warner; Gary H Lyman; Patricia A Ganz Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Dominique Frechette; Lise Paquet; Shailendra Verma; Mark Clemons; Paul Wheatley-Price; Stan Z Gertler; Xinni Song; Nadine Graham; Susan Dent Journal: Breast Cancer Res Treat Date: 2013-08-14 Impact factor: 4.872
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Neha Verma; Amanda L Blackford; Elissa Thorner; Jennifer Lehman; Claire Snyder; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2022-10-05 Impact factor: 4.624
Authors: Angelique Bobrie; Marta Jarlier; Aurore Moussion; William Jacot; Veronique D'Hondt Journal: Support Care Cancer Date: 2022-01-14 Impact factor: 3.359